NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Forecast, Price & News $10.15 -0.22 (-2.12%) (As of 05:37 PM ET) Add Compare Share Share Today's Range$9.83▼$10.3650-Day Range$10.26▼$15.7052-Week Range$5.84▼$17.02Volume469,768 shsAverage Volume395,157 shsMarket Capitalization$576.52 millionP/E RatioN/ADividend YieldN/APrice Target$23.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Phathom Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.9% Upside$23.33 Price TargetShort InterestBearish10.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.07) to ($4.68) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector563rd out of 969 stocksPharmaceutical Preparations Industry265th out of 452 stocks 3.5 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.33, Phathom Pharmaceuticals has a forecasted upside of 129.9% from its current price of $10.15.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.76% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently decreased by 0.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 2.7 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest4 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Phathom Pharmaceuticals is held by insiders.Percentage Held by Institutions93.14% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to decrease in the coming year, from ($4.07) to ($4.68) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Phathom Pharmaceuticals (NASDAQ:PHAT) StockPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)September 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Cardiff Oncology (CRDF) and Streamline Health Solutions (STRM)October 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 26, 2023 | msn.comPhathom files for FDA approval of vonoprazan for Non-Erosive GERDSeptember 26, 2023 | markets.businessinsider.comPhathom Pharma Submits NDA To FDA For Vonoprazan To Treat Non-Erosive GERDSeptember 26, 2023 | finance.yahoo.comPhathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERDSeptember 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Xenon (XENE) and TRACON Pharmaceuticals (TCON)August 30, 2023 | msn.comPhathom Pharmaceuticals (PHAT) Price Target Increased by 18.15% to 22.29October 2, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.August 25, 2023 | prnewswire.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)August 24, 2023 | finance.yahoo.comReflux Testing Products Global Market Report 2023August 22, 2023 | seekingalpha.comPhathom submits additional data to FDA for esophagitis candidateAugust 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP) and Phathom Pharmaceuticals (PHAT)August 21, 2023 | finance.yahoo.comPhathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug ApplicationAugust 18, 2023 | markets.businessinsider.comJonesTrading downgrades Impel Pharmaceuticals (IMPL) to a HoldAugust 11, 2023 | msn.comHC Wainwright & Co. Reiterates Phathom Pharmaceuticals (PHAT) Buy RecommendationAugust 10, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Hold Rating on Phathom Pharmaceuticals (PHAT)August 10, 2023 | msn.comPhathom Pharmaceuticals GAAP EPS of -$0.84 beats by $0.14August 10, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy RecommendationAugust 10, 2023 | finance.yahoo.comPhathom Pharmaceuticals Reports Second Quarter 2023 ResultsAugust 7, 2023 | markets.businessinsider.comJonesTrading Keeps Their Buy Rating on Ovid Therapeutics (OVID)August 4, 2023 | markets.businessinsider.comJonesTrading Remains a Buy on Longboard Pharmaceuticals (LBPH)July 23, 2023 | fool.comPhathom Pharmaceuticals (NASDAQ: PHAT)July 14, 2023 | seekingalpha.comPhathom Pharma: Time To Take Profits (Rating Downgrade)July 7, 2023 | finance.yahoo.com3 Top Breakout Stocks Worth a Buy for Attractive ReturnsJuly 7, 2023 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Phathom Pharmaceuticals StockJune 26, 2023 | markets.businessinsider.comStoke Therapeutics (STOK) Gets a Buy from NeedhamSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Company Calendar Last Earnings8/10/2023Today10/02/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees112Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.33 High Stock Price Forecast$30.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+127.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-197,720,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-95.34% Debt Debt-to-Equity Ratio5.56 Current Ratio11.96 Quick Ratio11.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.80) per share Price / Book-5.71Miscellaneous Outstanding Shares56,800,000Free Float52,543,000Market Cap$583.90 million OptionableNot Optionable Beta0.56 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 54)Pres, CEO & Director Comp: $1.11MMr. David A. Socks (Age 48)Co-Founder & Director Comp: $58.78kDr. Azmi Nabulsi M.D. (Age 63)M.P.H., Co-Founder & COO Comp: $815.21kMs. Molly Henderson CPA (Age 52)MBA, Chief Financial & Bus. Officer Comp: $671.27kMr. Aditya Kohli Ph.D. (Age 35)Co-Founder Mr. Anthony J. Guzzo (Age 50)Chief Accounting Officer Mr. Joseph Hand J.D.Chief Admin. OfficerMr. Lawrence Miller Esq.J.D., Gen. Counsel & Sec.Mr. Tom HarrisChief Devel. Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsTyra BiosciencesNASDAQ:TYRAAlpine Immune SciencesNASDAQ:ALPNEnliven TherapeuticsNASDAQ:ELVNCentessa PharmaceuticalsNASDAQ:CNTARAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsBarclays PLCSold 1,713 shares on 9/21/2023Ownership: 0.019%California State Teachers Retirement SystemBought 11,541 shares on 8/21/2023Ownership: 0.065%Osaic Holdings Inc.Bought 4,100 shares on 8/21/2023Ownership: 0.007%Nuveen Asset Management LLCBought 73,325 shares on 8/16/2023Ownership: 0.416%Citadel Advisors LLCBought 3,400 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PHAT Stock - Frequently Asked Questions Should I buy or sell Phathom Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PHAT shares. View PHAT analyst ratings or view top-rated stocks. What is Phathom Pharmaceuticals' stock price forecast for 2023? 7 analysts have issued twelve-month price objectives for Phathom Pharmaceuticals' stock. Their PHAT share price forecasts range from $16.00 to $30.00. On average, they predict the company's stock price to reach $23.33 in the next year. This suggests a possible upside of 127.0% from the stock's current price. View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts. How have PHAT shares performed in 2023? Phathom Pharmaceuticals' stock was trading at $11.22 at the beginning of 2023. Since then, PHAT shares have decreased by 8.4% and is now trading at $10.28. View the best growth stocks for 2023 here. When is Phathom Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our PHAT earnings forecast. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, August, 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.11. What ETFs hold Phathom Pharmaceuticals' stock? ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED). When did Phathom Pharmaceuticals IPO? (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. What is Phathom Pharmaceuticals' stock symbol? Phathom Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAT." How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Phathom Pharmaceuticals' stock price today? One share of PHAT stock can currently be purchased for approximately $10.28. How much money does Phathom Pharmaceuticals make? Phathom Pharmaceuticals (NASDAQ:PHAT) has a market capitalization of $583.90 million. The company earns $-197,720,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis. How many employees does Phathom Pharmaceuticals have? The company employs 112 workers across the globe. How can I contact Phathom Pharmaceuticals? Phathom Pharmaceuticals' mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The official website for the company is www.phathompharma.com. The company can be reached via phone at 877-742-8466 or via email at ir@phathompharma.com. This page (NASDAQ:PHAT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.